Shorter Sleep Duration Associated With Osteoporosis in Postmenopausal Women
Epidemiologic data indicate that shorter sleep duration (≤5 hours per night) is associated with lower bone mineral density in postmenopausal women.
Osteoporosis
Cardiovascular Effects of Denosumab and Romosozumab in Osteoporosis
In a meta-analysis, researchers aimed to explore the association between denosumab and romosozumab and cardiovascular risk in patients with primary osteoporosis.
Fracture Risk, BMD Improvement With Abaloparatide Plus Alendronate in Osteoporosis, OA
In this post hoc analysis, researchers evaluated the efficacy and safety of abaloparatide followed by alendronate vs placebo followed by alendronate in a subgroup of patients with osteoarthritis.
Severely Energy-Restricted Diet Effective for Obesity But Carries Risk for Bone Loss
For postmenopausal women with obesity, a severely energy-restricted diet resulted in a 2-fold greater decrease in weight compared with a moderately restricted diet, but was also associated with a much higher risk for loss of bone mineral density.
The Independent Role of Elevated Serum Calcium on Bone Metabolism
Elevated calcium levels may lead to suboptimal growth of bone, according to the study’s findings.
Large BMD Gains With Second Course of Romosozumab in Postmenopausal Women
A second course of romosozumab led to either gains in or maintenance of bone mineral density in postmenopausal women who were 12 months off treatment or transitioning from denosumab.
Meta-Analysis: Nonbisphosphonates Reduce Fracture Risk in Osteoporosis
Nonbisphosphonates, including denosumab, raloxifene, romosozumab, and teriparatide, significantly reduce vertebral fractures and benefit femoral neck bone mineral density compared with placebo.
Marked Heterogeneity in Osteoporosis Treatment Preferences Found Among Patients
In patients with osteoporosis, treatment preference varies but is not related to specific patient characteristics.
Risperidone Treatment Not Linked to Osteoporosis Fracture Risk
Risperidone treatment may not be associated with an increased risk for osteoporosis-related fractures compared with other atypical antipsychotic medications, according to study results published in Acta Psychiatrica Scandinavica. Researchers conducted a nationwide cohort study comparing the risk for osteoporosis-related fractures in patients treated with risperidone vs other atypical and typical antipsychotic medications. Investigators specifically evaluated…
Bone Characteristics by QCT in Patients With Normal vs Abnormal Glucose Tolerance
Diagnosis of osteoporosis based on QCT analysis is more common in patients with diabetes and impaired glucose tolerance compared with patients with normal glucose tolerance.
Next post in Bone Metabolism
